Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:JNJ NYSE:NVS OTCMKTS:RHHBY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeJNJJohnson & Johnson$177.71-0.2%$167.53$140.68▼$181.16$426.69B0.47.67 million shs6.83 million shsNVSNovartis$128.13+1.2%$120.90$96.06▼$128.44$267.33B0.631.17 million shs1.29 million shsRHHBYRoche$42.05+2.5%$40.14$34.10▼$44.31$259.43B0.471.43 million shs2.66 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceJNJJohnson & Johnson+0.40%+0.67%+6.26%+15.92%+7.21%NVSNovartis+0.18%0.00%+9.87%+8.15%+4.75%RHHBYRoche+0.61%+1.64%+5.61%+0.54%-3.09%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationJNJJohnson & Johnson4.6089 of 5 stars2.33.04.23.92.91.71.9NVSNovartis2.688 of 5 stars1.15.02.50.04.20.01.9RHHBYRocheN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceJNJJohnson & Johnson 2.65Moderate Buy$176.29-0.80% DownsideNVSNovartis 2.10Hold$123.50-3.62% DownsideRHHBYRoche 2.57Moderate BuyN/AN/ACurrent Analyst Ratings BreakdownLatest JNJ, RHHBY, and NVS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025NVSNovartisDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/21/2025JNJJohnson & JohnsonCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$185.00 ➝ $200.008/8/2025NVSNovartisMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeUnderweight ➝ Equal Weight$123.007/23/2025JNJJohnson & JohnsonErste Group BankSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy7/17/2025JNJJohnson & JohnsonPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight7/17/2025JNJJohnson & JohnsonBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$165.00 ➝ $176.007/17/2025JNJJohnson & JohnsonRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$181.00 ➝ $185.007/17/2025JNJJohnson & JohnsonUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$180.00 ➝ $190.007/17/2025JNJJohnson & JohnsonGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$164.00 ➝ $167.007/17/2025JNJJohnson & JohnsonBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$161.00 ➝ $175.007/17/2025JNJJohnson & JohnsonMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetEqual Weight ➝ Equal Weight$171.00 ➝ $176.00(Data available from 9/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookJNJJohnson & Johnson$88.82B4.82$13.16 per share13.50$32.58 per share5.45NVSNovartis$50.32B5.38$10.83 per share11.83$19.91 per share6.44RHHBYRoche$68.73B3.89$3.41 per share12.34$6.46 per share6.51Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateJNJJohnson & Johnson$14.07B$9.3519.0116.052.2625.00%32.49%13.00%10/21/2025 (Estimated)NVSNovartis$11.94B$6.8718.6514.541.7725.64%41.08%16.83%11/4/2025 (Estimated)RHHBYRoche$9.40BN/A0.0014.022.24N/AN/AN/AN/ALatest JNJ, RHHBY, and NVS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/17/2025Q2 2025NVSNovartis$2.38$2.42+$0.04$2.06$13.94 billion$14.05 billion7/16/2025Q2 2025JNJJohnson & Johnson$2.68$2.77+$0.09$2.29$22.85 billion$23.74 billionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthJNJJohnson & Johnson$5.202.93%N/A55.61%64 YearsNVSNovartis$2.602.03%N/A37.85%N/ARHHBYRoche$0.872.07%N/AN/AN/ALatest JNJ, RHHBY, and NVS DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date7/16/2025JNJJohnson & Johnsonquarterly$1.303.35%8/26/20258/26/20259/9/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioJNJJohnson & Johnson0.501.010.76NVSNovartis0.530.820.62RHHBYRoche0.851.481.20Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipJNJJohnson & Johnson69.55%NVSNovartis13.12%RHHBYRocheN/AInsider OwnershipCompanyInsider OwnershipJNJJohnson & Johnson0.16%NVSNovartis0.01%RHHBYRocheN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableJNJJohnson & Johnson138,1002.41 billion2.40 billionOptionableNVSNovartis75,8832.11 billion2.11 billionOptionableRHHBYRoche103,2496.36 billionN/ANot OptionableJNJ, RHHBY, and NVS HeadlinesRecent News About These CompaniesGlobal drugmakers rush to boost US presence as tariff threat loomsSeptember 3 at 2:09 PM | reuters.comRoche Holding AG (OTCMKTS:RHHBY) Receives Average Rating of "Moderate Buy" from BrokeragesSeptember 3 at 3:08 AM | marketbeat.comRoche and Alnylam advance zilebesiran into global phase III cardiovascular outcomes trial for people with uncontrolled hypertensionAugust 30, 2025 | globenewswire.comGenentech and Alnylam Advance Zilebesiran Into Global Phase III Cardiovascular Outcomes Trial for People With Uncontrolled HypertensionAugust 30, 2025 | businesswire.comFinancial Survey: Roche (OTCMKTS:RHHBY) vs. Sanofi (NASDAQ:SNY)August 27, 2025 | americanbankingnews.comF. Hoffmann-La Roche Ltd: Roche's US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USAAugust 25, 2025 | finanznachrichten.deRoche’s US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USAAugust 25, 2025 | finance.yahoo.comRoche's US subsidiary Genentech breaks ground on state-of-the-art manufacturing facility in North Carolina, USAAugust 25, 2025 | globenewswire.comGenentech and Roche Break Ground on State-of-the-Art Manufacturing Facility in Holly Springs, North CarolinaAugust 25, 2025 | businesswire.comCorient IA LLC Takes Position in Roche Holding AG (OTCMKTS:RHHBY)August 19, 2025 | marketbeat.comFCA Corp TX Invests $494,000 in Roche Holding AG (OTCMKTS:RHHBY)August 16, 2025 | marketbeat.comPharma tariff announcement likely ‘weeks away,’ Reuters reportsAugust 14, 2025 | msn.comH.C. Wainwright doubles Insmed target to $240 on ‘pipeline-in-a-pill’ potentialAugust 13, 2025 | msn.comHC Wainwright Doubles Price Target On Insmed After Brinsupri Approval: Retail Expects Stock To Hit $150 By End Of WeekAugust 13, 2025 | msn.comRoche, Novartis due to meet Swiss govt. amid Trump’s tariff threats: ReutersAugust 11, 2025 | msn.comSwiss leaders to discuss tariff situation with Roche, Novartis, Bloomberg saysAugust 11, 2025 | msn.comEverett Harris & Co. CA Makes New $445,000 Investment in Roche Holding AG (OTCMKTS:RHHBY)August 10, 2025 | marketbeat.comRoche Holding AG (OTCMKTS:RHHBY) Receives Average Recommendation of "Moderate Buy" from BrokeragesAugust 9, 2025 | marketbeat.comSA Asks: How could Trump's drug pricing demands impact stocks?August 8, 2025 | msn.comTrump administration reportedly seeks higher ex-US drug prices in pursuit of MFN policyAugust 8, 2025 | msn.comGenentech’s Susvimo Maintains Vision Over Five Years With Two Refills Per Year in People With Wet Age-Related Macular Degeneration (AMD)August 1, 2025 | joplinglobe.comJNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025JNJ Stock Surge Signals Confidence in New Growth PathBy Jeffrey Neal Johnson | August 25, 2025Worried About a Fading Rally? Consider These 3 Dividend StocksBy Dan Schmidt | August 11, 2025JNJ, RHHBY, and NVS Company DescriptionsJohnson & Johnson NYSE:JNJ$177.71 -0.35 (-0.20%) Closing price 03:59 PM EasternExtended Trading$177.06 -0.64 (-0.36%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.Novartis NYSE:NVS$128.13 +1.49 (+1.18%) Closing price 03:59 PM EasternExtended Trading$127.89 -0.24 (-0.19%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol; and Dawn Health for the development and commercialization of Ekiva, a digital solution designed for people living with Paroxysmal Nocturnal Hemoglobinuria. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.Roche OTCMKTS:RHHBY$42.05 +1.03 (+2.51%) As of 03:59 PM EasternRoche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Zscaler Shares Can Hit a Fresh High Before Year-End Why Qualcomm Is Outperforming NVIDIA After Months of Lagging Alphabet Stock Surges After Dodging Harsh Antitrust Remedies Wall Street Punishes Dell's Record Quarter: Why They Are Wrong Taiwan Semiconductor Falls on China News—Buy The Dip? CrowdStrike Tests $412 Support as Options Traders Turn Bullish What to Expect From the Q3 Reporting Season IREN Is Up 186% YTD on AI Pivot—And It’s Just Getting Started Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
